Published in Cancer Weekly, December 4th, 1995
The results in seven patients form part of the Phase I/II study with SNX-111 which was sponsored by Neurex Corporation, Menlo Park, California, and was conducted at several centers in the U.S.
"Based on what I have seen in the patients I have treated, SNX-111 has the potential to provide symptomatic relief in patients who have failed all other pain therapy, without the typical side effects seen with opiates," Brose...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.